12,372 trials
Psoriasis
Primary: Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12 — 11.0; 57.0 percentage of participants…
Cystic Fibrosis
Primary: Treatment Emergent Adverse Events (TEAEs) up to Day 672 — 183; 92; 21 Participants
Gestational Diabetes Mellitus · Type 2 Diabetes Mellitus · Metabolic Syndrome
Primary: Insulin Secretion-Sensitivity Index (IS-SI) — 418.4; 333 index — p=<0.04
Rhinitis, Allergic
Primary: Change From Baseline in Total Nasal Symptom Score (Assessed by Participant) — 7.9; 7.8; 7.9; 8.0 Score on a scale — p=0.36
Upper Airway Obstruction · Respiratory Insufficiency · Respiratory Failure
Primary: Oxygen Desaturation Index 4% (ODI4%) — 3.16; 7.61 events per hour — p=0.0134
Schizophrenia
Primary: Change From Baseline to Week 48 in the PANSS Total Score — 66.5; -5.0 Units on a scale
Bipolar Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 6 — -10.6; -13.6; -12.6 units on a scale — p=0.007
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Primary: Change From Baseline at Week 24 in Nasal Congestion/Obstruction Symptom Severity Score — -0.45; -1.34 score on a scale — p=<0.0001
Acute Pain
Primary: Pain Relief Expressed as Total Pain Relief (TOTPAR) Over the 4 Hours Post-dose Period (TOTPAR4) — 9.9; 8.6; 5.4; 5.8 units on a scale — p=<0.0001
COPD, Chronic Obstructive Pulmonary Disease
Primary: Specific Image-Based Airway Volume (siVaw) — 1.11; 1.23 ratio — p=0.0187
Dengue Fever · Dengue Hemorrhagic Fever
Primary: Post-Dose 3 Geometric Mean Titers (GMTs) of Antibodies Against Each of the Four Dengue Virus Serotypes Following Vaccination With Phase III Lots of CYD Dengue Vaccine…
Narcolepsy
Primary: Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 — 2.12; 4.74; 9.77; 12.27 minutes
Obstructive Sleep Apnea
Primary: Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12 — 4.74; 9.08; 10.96; 12.99 minutes
Depression · End Stage Renal Disease
Primary: Number of Participants Who Initiated Depression Treatment — 57; 54 Participants — p=0.77
Cataract · Macular Degeneration
Primary: Number of Participants With Visually Significant Age-related Macular Degeneration (AMD) — 9; 12; 9; 12 Participants — p=0.52